Overview

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Status:
Withdrawn
Trial end date:
2017-07-07
Target enrollment:
Participant gender:
Summary
An oral dose of BMS-986141 administered in Hepatic Impairment and Healthy Participants to evaluate pharmacokinetics in this patient population.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb